Lataa...
Trial Watch: Adoptive cell transfer for oncological indications
One particular paradigm of anticancer immunotherapy relies on the administration of (potentially) tumor-reactive immune effector cells. Generally, these cells are obtained from autologous peripheral blood lymphocytes (PBLs) ex vivo (in the context of appropriate expansion, activation and targeting p...
Tallennettuna:
| Julkaisussa: | Oncoimmunology |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4590013/ https://ncbi.nlm.nih.gov/pubmed/26451319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046673 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|